raloxifene hydrochloride has been researched along with arginyl-glycyl-aspartic acid in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baby, T; Bulbule, A; Gorain, M; Kundu, GC; Radharani, NNV; Roy, G; Shetti, D; Yadav, AS | 1 |
1 other study(ies) available for raloxifene hydrochloride and arginyl-glycyl-aspartic acid
| Article | Year |
|---|---|
RGD functionalized chitosan nanoparticle mediated targeted delivery of raloxifene selectively suppresses angiogenesis and tumor growth in breast cancer.
Topics: Breast Neoplasms; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Humans; Nanoparticles; Oligopeptides; Raloxifene Hydrochloride; Tumor Microenvironment | 2020 |